Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.59 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | AKT2 | P31751 | 1/20 | 0.44 |
| ▸ | TACR1 | P25103 | 4/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | ADK | P55263 | 1/20 | 0.37 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6032011 | 0.80 | OPRM1 (0.53) | OPRM1TACR1MTORADKNISCH | |
| SCHEMBL738518 | 0.76 | OPRM1 (1.00) | OPRM1HTR2AAKT2TACR1MEN1 | |
| SCHEMBL27999872 | 0.76 | F10 (0.35) | MEN1CYP2C9TSHRKMT2ACYP3A4 | |
| Hydrochloric Acid SCHEMBL1765284 | 0.74 | OPRM1 (0.95) | OPRM1HTR2AAKT2TACR1MEN1 | |
| SCHEMBL28000139 | 0.74 | DGAT2 (0.34) | OPRM1MEN1CYP2C9TSHRKMT2A | |
| SCHEMBL21788599 | 0.73 | OPRM1 (0.63) | OPRM1HTR2AAKT2TACR1MEN1 | |
| SCHEMBL8351479 | 0.73 | NISCH (0.44) | OPRM1NISCHMEN1CYP2C9TSHR | |
| SCHEMBL20493612 | 0.73 | CYP2D6 (0.46) | OPRM1TACR1NISCHMEN1CYP2C9 | |
| SCHEMBL2309386 | 0.72 | OPRM1 (0.56) | OPRM1HTR2AAKT2MEN1TSHR | |
| SCHEMBL8353505 | 0.71 | NISCH (0.42) | OPRM1NISCHMEN1CYP2C9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2298744-B1 | Opioid receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2013-06-26 | — | — | EP | disclosed |
| US-7390822-B2 | Substituted 4-phenyl-4-[1H-imidazol-2-yl]-piperidine derivatives for reducing ischaemic damage | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-06-24 | — | — | US | disclosed |
| US-7390822-B2 | Substituted 4-phenyl-4-[1H-imidazol-2-yl]-piperidine derivatives for reducing ischaemic damage | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-06-24 | — | — | US | disclosed |
| US-7390822-B2 | Substituted 4-phenyl-4-[1H-imidazol-2-yl]-piperidine derivatives for reducing ischaemic damage | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-06-24 | — | — | US | disclosed |
| US-20080096925-A1 | Novel Substituted 4-Phenyl-4[H-Imidazol-2-YL]-Piperidine Derivatived And Their Use As Selective Non-Peptide Delta Opioid Agonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-24 | — | — | US | disclosed |
| US-20080096925-A1 | Novel Substituted 4-Phenyl-4[H-Imidazol-2-YL]-Piperidine Derivatived And Their Use As Selective Non-Peptide Delta Opioid Agonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-24 | — | — | US | disclosed |
| CN-100354273-C | Substituted 4-phenyl-4- (1H-imidazol-2-yl) -piperidine derivatives and their use as selective non-peptide delta opioid agonists | JANSSEN PHARMACEUTICA NV (BE) | 2007-12-12 | — | — | CN | disclosed |
| CN-100354273-C | Substituted 4-phenyl-4- (1H-imidazol-2-yl) -piperidine derivatives and their use as selective non-peptide delta opioid agonists | JANSSEN PHARMACEUTICA NV (BE) | 2007-12-12 | — | — | CN | disclosed |
| CN-100354273-C | Substituted 4-phenyl-4- (1H-imidazol-2-yl) -piperidine derivatives and their use as selective non-peptide delta opioid agonists | JANSSEN PHARMACEUTICA NV (BE) | 2007-12-12 | — | — | CN | disclosed |
| US-7282508-B2 | Substituted 4-phenyl-4-(1H-imidazol-2-yl)-piperidine derivatives and their use as selective non-peptide delta opioid agonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-16 | — | — | US | disclosed |
| WO-2004089372-A1 | SUBSTITUTED 4-PHENYL-4-`1H-IMIDAZOL-2-YL !-PIPERIDINE DERIVATIVES AND THEIR USE AS SELECTIVE NON-PEPTIDE DELTA OPIOID AGONISTS WITH ANTIDEPRESSANT AND ANXIOLYTIC ACTIVITY | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-10-21 | — | — | WO | disclosed |
| EP-1438049-A2 | SUBSTITUTED 4-PHENYL-4-(1H-IMIDAZOL-2-YL)-PIPERIDINE DERIVATIVES FOR REDUCING ISCHAEMIC DAMAGE | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-07-21 | — | — | EP | disclosed |
| EP-1438049-A2 | SUBSTITUTED 4-PHENYL-4-(1H-IMIDAZOL-2-YL)-PIPERIDINE DERIVATIVES FOR REDUCING ISCHAEMIC DAMAGE | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-07-21 | — | — | EP | disclosed |
| EP-1438304-A1 | NOVEL SUBSTITUTED 4-PHENYL-4- 1H-IMIDAZOL-2-YL]-PIPERIDINE DERIVATIVES AND THEIR USE AS SELECTIVE NON-PEPTIDE DELTA OPIOID AGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-07-21 | — | — | EP | disclosed |
| EP-1438304-A1 | NOVEL SUBSTITUTED 4-PHENYL-4- 1H-IMIDAZOL-2-YL]-PIPERIDINE DERIVATIVES AND THEIR USE AS SELECTIVE NON-PEPTIDE DELTA OPIOID AGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-07-21 | — | — | EP | disclosed |
| WO-2003039440-A3 | SUBSTITUTED 4-PHENYL-4-(1H-IMIDAZOL-2-YL)-PIPERIDINE DERIVATIVES FOR REDUCING ISCHAEMIC DAMAGE | JANSSEN PHARMACEUTICA NV (BE) | 2003-12-18 | — | — | WO | disclosed |
| WO-2003039440-A2 | SUBSTITUTED 4-PHENYL-4-(1H-IMIDAZOL-2-YL)-PIPERIDINE DERIVATIVES FOR REDUCING ISCHAEMIC DAMAGE | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-05-15 | — | — | WO | disclosed |
| WO-2003039440-A2 | SUBSTITUTED 4-PHENYL-4-(1H-IMIDAZOL-2-YL)-PIPERIDINE DERIVATIVES FOR REDUCING ISCHAEMIC DAMAGE | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-05-15 | — | — | WO | disclosed |
| WO-2003033486-A1 | NOVEL SUBSTITUTED 4-PHENYL-4-[1H-IMIDAZOL-2-YL]-PIPERIDINE DERIVATIVES AND THEIR USE AS SELECTIVE NON-PEPTIDE DELTA OPIOID AGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-04-24 | — | — | WO | disclosed |
| WO-2003033486-A1 | NOVEL SUBSTITUTED 4-PHENYL-4-[1H-IMIDAZOL-2-YL]-PIPERIDINE DERIVATIVES AND THEIR USE AS SELECTIVE NON-PEPTIDE DELTA OPIOID AGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096925-A1 | Novel Substituted 4-Phenyl-4[H-Imidazol-2-YL]-Piperidine Derivatived And Their Use As Selective Non-Peptide Delta Opioid Agonists | OPRD1, OPRK1, OPRL1 | OPRM1 4/4885HTR2A 662/4885AKT2 2974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.